These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36038720)

  • 1. Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study.
    Iglicki M; Khoury M; Melamud JI; Donato L; Barak A; Quispe DJ; Zur D; Loewenstein A
    Eye (Lond); 2023 Jun; 37(8):1659-1664. PubMed ID: 36038720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. "The Submarine Study".
    Iglicki M; Khoury M; Donato L; Quispe DJ; Negri HP; Melamud JI
    Eye (Lond); 2024 Feb; 38(2):292-296. PubMed ID: 37537388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study.
    Szeto SKH; Tsang CW; Mohamed S; Lee GKY; Lok JKH; Hui VWK; Tsang KK; Chen LJ; Brelen M; Lai TYY
    Ophthalmologica; 2024; 247(2):118-132. PubMed ID: 38408445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
    Jackson TL; Bunce C; Desai R; Hillenkamp J; Lee CN; Lois N; Peto T; Reeves BC; Steel DH; Edwards RT; van Meurs JC; Wafa H; Wang Y
    Trials; 2022 Jan; 23(1):99. PubMed ID: 35101110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
    Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.
    Tranos P; Tsiropoulos GN; Koronis S; Vakalis A; Asteriadis S; Stavrakas P
    Int Ophthalmol; 2021 Dec; 41(12):4037-4046. PubMed ID: 34331185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
    Gabrielle PH; Delyfer MN; Glacet-Bernard A; Conart JB; Uzzan J; Kodjikian L; Arndt C; Tadayoni R; Soudry-Faure A; Creuzot Garcher CP
    Ophthalmology; 2023 Sep; 130(9):947-957. PubMed ID: 37088447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fundus Autofluorescence Patterns in Subretinal Hemorrhages Associated with Neovascular Age-Related Macular Degeneration.
    Nawrocka ZA; Nawrocki J
    Ophthalmologica; 2024; 247(1):58-64. PubMed ID: 38113868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
    Fassbender JM; Sherman MP; Barr CC; Schaal S
    Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration.
    Sniatecki JJ; Ho-Yen G; Clarke B; Barbara R; Lash S; Papathomas T; Antonakis S; Gupta B
    Eur J Ophthalmol; 2021 Mar; 31(2):643-648. PubMed ID: 31813290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between different techniques for treatment of submacular haemorrhage due to Age-Related Macular Degeneration.
    Kishikova L; Saad AAA; Vaideanu-Collins D; Isac M; Hamada D; El-Haig WM
    Eur J Ophthalmol; 2021 Sep; 31(5):2621-2624. PubMed ID: 32993349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for visual acuity improvement after treatment of submacular hemorrhage secondary to exudative age-related macular degeneration.
    Barayev E; Tiosano A; Zlatkin R; Elul R; Dotan A; Hadayer A; Gal-Or O; Ehrlich R
    Eur J Ophthalmol; 2024 May; 34(3):825-833. PubMed ID: 37715632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of submacular massive haemorrhage in age-related macular degeneration: comparison between subretinal transplant of human amniotic membrane and subretinal injection of tissue plasminogen activator.
    Caporossi T; Bacherini D; Governatori L; Oliverio L; Di Leo L; Tartaro R; Rizzo S
    Acta Ophthalmol; 2022 Aug; 100(5):e1143-e1152. PubMed ID: 34609787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early surgical displacement of submacular hemorrhage without tissue plasminogen activator use: one-year outcomes.
    Abdulaal M; Donkor R; Robertson J; Lewis S; Miller DG; Schartman J; Platt S; Coney JM
    Can J Ophthalmol; 2024 Oct; 59(5):e582-e589. PubMed ID: 37925165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumatic Displacement of Submacular Hemorrhage with Subretinal Air and Tissue Plasminogen Activator: Initial United States Experience.
    Sharma S; Kumar JB; Kim JE; Thordsen J; Dayani P; Ober M; Mahmoud TH
    Ophthalmol Retina; 2018 Mar; 2(3):180-186. PubMed ID: 31047581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gravitational displacement of submacular haemorrhage in patients with age-related macular disease.
    Erdogan G; Kirmaci A; Perente I; Artunay O
    Eye (Lond); 2020 Jun; 34(6):1136-1141. PubMed ID: 31792350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
    Bardak H; Bardak Y; Erçalık Y; Erdem B; Arslan G; Timlioglu S
    Eur J Ophthalmol; 2018 May; 28(3):306-310. PubMed ID: 29148027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of submacular hemorrhage with low-dose subretinal recombinant tissue plasminogen activator and intravitreal conbercept.
    Ma Y; Rao S; Tan Y; Du H; Sun X
    BMC Ophthalmol; 2024 Sep; 24(1):395. PubMed ID: 39237907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.